New Releases from NCBI BookshelfElranatamab (Elrexfio): Therapeutic area: Relapsed or refractory multiple myeloma: Reimbursement Review [Internet].Elranatamab (Elrexfio): Therapeutic area: Relapsed or refractory multiple myeloma: Reimbursement Review [Internet].By / December 18, 2024 Post Content